{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:22:01Z","timestamp":1793917321955,"version":"4.8.0"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jccm-2020-0030_s_006_w2aab3b7b7b1b6b1aab1c15b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Vasopressors are conventionally administered through a central venous catheter (CVC) and not through a peripheral venous catheter (PVC) since the latter is believed to be associated with increased risk of extravasation. Placement of a CVC requires suitably trained personnel to be on hand, and in resource-limited settings, this requirement may delay placement. Because of this and in cases where suitably trained personnel are not immediately available, some clinicians may be prompted to utilise a PVC for infusing vasopressors. The objective of this study is to assess the feasibility and safety of vasopressors administered through a PVC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jccm-2020-0030_s_007_w2aab3b7b7b1b6b1aab1c15b2Aa\">\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Patients who received vasopressors through a PVC for more than one hour were included in a single centre, consecutive patient observational study. Patients with a CVC at the time of initiation of vasopressors were excluded. Data regarding the size, location of PVCs, dose, duration and number of vasopressors infused were recorded. The decision to place CVC was left to the discretion of the treating physician. Extravasation incidents, severity and management of such events were recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jccm-2020-0030_s_008_w2aab3b7b7b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred twenty-two patients age 55(4) years [mean (SD)] were included in the study. The commonest PVC was of 18G calibre (57%), and the most common site of placement was the external jugular vein (36.5%). Noradrenaline was the most common vasopressor used at a dose of 10.6 (7) mcg\/min [mean (SD)] and the median duration of nine hours (IQR: 6-14). CVC was placed most commonly due to an increasing dose of vasopressors after 4.5(4) hours [mean (SD)]. Grade 2 Extravasation injury occurred in one patient after prolonged infusion of fifty-two hours, through a small calibre (20G) PVC, which was managed conservatively without any sequelae.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jccm-2020-0030_s_009_w2aab3b7b7b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Vasopressors infused through a PVC of 18G or larger calibre into the external jugular, or a forearm vein is feasible and safe. Clinicians need to balance the safety of peripheral vasopressor infusion with the additional costs and complications associated with CVC in resource-limited settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2478\/jccm-2020-0030","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T08:12:03Z","timestamp":1605600723000},"page":"210-216","source":"Crossref","is-referenced-by-count":14,"title":["Feasibility and Safety of Peripheral Intravenous Administration of Vasopressor Agents in Resource-limited Settings"],"prefix":"10.2478","volume":"6","author":[{"given":"Ajay","family":"Padmanaban","sequence":"first","affiliation":[{"name":"Apollo Hospitals Chennai , Chennai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Venkataraman","sequence":"additional","affiliation":[{"name":"Apollo Hospitals Chennai , Chennai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilkumar","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Apollo Hospitals Chennai , Chennai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedeepiya","family":"Devaprasad","sequence":"additional","affiliation":[{"name":"Apollo Cancer Hospitals , Chennai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Apollo Hospitals Chennai , Chennai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"2023122812404455361_j_jccm-2020-0030_ref_001_w2aab3b7b7b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Kahn JM, Kress JP, Hall JB. Skin necrosis after extravasation of low-dose vasopressin administered for septic shock. Crit Care Med. 2002;30(8):1899\u2013901.","DOI":"10.1097\/00003246-200208000-00038"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_002_w2aab3b7b7b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Bunker N, Higgins D. Peripheral administration of vasopressin for catecholamine-resistant hypotension complicated by skin necrosis. Crit Care Med. 2006;34(3):935.","DOI":"10.1097\/01.CCM.0000202202.85087.37"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_003_w2aab3b7b7b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"McGee DC, Gould MK. Preventing complications of central venous catheterisation. N Engl J Med. 2003;348(12):1123\u201333.","DOI":"10.1056\/NEJMra011883"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_004_w2aab3b7b7b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Polderman KH, Girbes ARJ. Central venous catheter use: Part 2: Infectious complications. Intensive Care Med. 2002;28(1):18\u201328.","DOI":"10.1007\/s00134-001-1156-7"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_005_w2aab3b7b7b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Beck V, Chateau D, Bryson GL, et al. Timing of vasopressor initiation and mortality in septic shock: A cohort study. Crit Care. 2014;18(3): R97.","DOI":"10.1186\/cc13868"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_006_w2aab3b7b7b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from the administration of vasopressors through peripheral intravenous catheters and central venous catheters. J Crit Care. 2015;30(3):653.e9-17.","DOI":"10.1016\/j.jcrc.2015.01.014"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_007_w2aab3b7b7b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Cardenas-Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581\u20135.","DOI":"10.1002\/jhm.2394"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_008_w2aab3b7b7b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Lewis T, Merchan C, Altshuler D, Papadopoulos J. Safety of the Peripheral Administration of Vasopressor Agents. J Intensive Care Med. 2019;34(1):26\u201333.","DOI":"10.1177\/0885066616686035"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_009_w2aab3b7b7b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Gorski LA. Infusion nursing standards of practice. J Infus Nurs. 2007;30(1):20\u20131.","DOI":"10.1097\/00129804-200701000-00004"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_010_w2aab3b7b7b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Reynolds PM, Maclaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: A focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617\u201332.","DOI":"10.1002\/phar.1396"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_011_w2aab3b7b7b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486\u2013552.","DOI":"10.1097\/CCM.0000000000002255"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_012_w2aab3b7b7b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Rachoin JS, Dellinger RP. Timing of norepinephrine in septic patients: NOT too little too late. Crit Care. 2014;18(6):691.","DOI":"10.1186\/s13054-014-0691-x"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_013_w2aab3b7b7b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Bai X, Yu W, Ji W, et al. Early versus delayed administration of norepinephrine in patients with septic shock. Crit Care. 2014;18(5):532.","DOI":"10.1186\/s13054-014-0532-y"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_014_w2aab3b7b7b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Geldenhuys C, Dramowski A, Jenkins A, Bekker A. Central-line-associated bloodstream infections in a resource-limited South African neonatal intensive care unit. South African Med J. 2017;107(9):758\u201362.","DOI":"10.7196\/SAMJ.2017.v107i9.12124"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_015_w2aab3b7b7b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Delgado T, Wolfe B, Davis G, Ansari S. Safety of peripheral administration of phenylephrine in a neurologic intensive care unit: A pilot study. J Crit Care. 2016;34:107\u201310.","DOI":"10.1016\/j.jcrc.2016.04.004"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_016_w2aab3b7b7b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Medlej K, Kazzi AA, El-Hajj Chehade A, et al. Complications from Administration of Vasopressors Through Peripheral Venous Catheters: An Observational Study. J Emerg Med. 2018;54(1):47\u201353.","DOI":"10.1016\/j.jemermed.2017.09.007"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_017_w2aab3b7b7b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Ricard JD, Salomon L, Boyer A, et al. Central or peripheral catheters for initial venous access of ICU patients: A randomised controlled trial. Crit Care Med. 2013;41(9):2108\u201315.","DOI":"10.1097\/CCM.0b013e31828a42c5"},{"key":"2023122812404455361_j_jccm-2020-0030_ref_018_w2aab3b7b7b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Giuffrida DJ, Bryan-Brown CW, Lumb PD, Kwun KB, Rhoades HM. Central vs peripheral venous catheters in critically ill patients. Chest. 1986;90(6):806\u20139.","DOI":"10.1378\/chest.90.6.806"}],"container-title":["The Journal of Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/jccm\/6\/4\/article-p210.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.sciendo.com\/pdf\/10.2478\/jccm-2020-0030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T12:47:50Z","timestamp":1703767670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.sciendo.com\/article\/10.2478\/jccm-2020-0030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,7]]},"published-print":{"date-parts":[[2020,11,7]]}},"alternative-id":["10.2478\/jccm-2020-0030"],"URL":"https:\/\/doi.org\/10.2478\/jccm-2020-0030","relation":{},"ISSN":["2393-1817"],"issn-type":[{"value":"2393-1817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}